Allan Bradley

Professor
University of Cambridge

Allan Bradley, Ph.D. is a Professor in the Cambridge Institute of Therapeutic Immunology and Infectious Disease at University of Cambridge. As a PhD student in Cambridge University, he conducted foundational work on embryonic stem cells which contributed to the 2007 Nobel Prize awarded for ES cell technology. Appointed as Howard Hughes Medical Institute Investigator at Baylor College of Medicine in Houston, Texas, USA, his laboratory played a seminal role in developing the techniques, technology and tools for genetic manipulation in the mouse, generating and analyzing many of the first generation of mouse knockouts as well as established chromosome engineering technology. In 2000, Dr. Bradley was appointed as Director of the Wellcome Trust Sanger Institute. During his 10-year term he established a new mission for the Institute, transforming it into an academic genome centre focused on genetic analysis of gene function. A few years ago he moved his laboratory back to Cambridge University.

Prof. Bradley is a serial entrepreneur, in 1995 he established Lexicon Genetics to industrialize mouse knockouts for drug-target discovery. Lexicon Genetics was floated on the NASDQ five years later. In 2000 he founded Spectral Genomics which developed micro-arrays for diagnosis of human disorders and was eventually sold to Perkin Elmer Inc. In 2010 he founded Kymab Limited, serving as Director and CSO. Kymab successfully engineered the most advanced mouse platform for discovery of human therapeutic antibodies, pioneered and applied single cell sequencing to B cells for antibody discovery and advanced several antibodies into clinical development. Kymab was recently acquired by Sanofi for $1.45bn. In 2017, he founded PetMedix Ltd, where he serves as the CSO & Director. PetMedix develops therapeutic antibodies for dogs and cats.